Peptides / Growth hormone axis

Synthetic analog · 8 amino acids · 1,019.2 Da

Octreotide

ApprovedNot banned in sport

Octreotide (Sandostatin) is a somatostatin analog approved in the US for acromegaly and for diarrhea caused by certain tumors, and in EU countries. Studies in people tested it on growth hormone, gut conditions, tumor growth and blood sugar, and tracked side effects. PepBank shows 711 results on octreotide from 118 studies in people, and 105 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as SMS 201-995, SMS-201-995, Sandostatin

8 amino acids, from first to lastFCFWKTCT

Evidence level: Large trials in people711 of 816 results come from studies in people, including randomized trials.

Results in people

711

87% of 816 results

Results in animals

105

13% of 816 results

Results in lab cells

0% of 816 results

From computer models

0% of 816 results

Overview

Octreotide at a glance

What it is	Synthetic analog, 8 amino acids
Approval	Approved in the US and EU (Sandostatin)
In sport	Not listed as banned by WADA
Studies	134 studies with results. All of them gave octreotide, with 816 results. 711 in people105 in animals
Best study in people	Randomized controlled trial with 667 people (2011)
Clinical trials	256 registered: 30 active or planned, 56 with posted results
Community use	Initial short-acting Sandostatin Injection for acromegaly after inadequate response to, or inability to receive, surgery, pituitary irradiation, and maximally tolerated bromocriptine.

The science

What is octreotide?

Octreotide is a cyclic eight-residue somatostatin analog.

Amino acids in one chain

The history of octreotide

1982
The oldest paper on octreotide in PepBank is from 1982.
2006September
A registered trial of octreotide started (NCT00966355).

Octreotide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 8 amino acidsFrom the first amino acid to the last

F1CFW+K5TCT

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Octreotide is a synthetic analog of 8 amino acids, with a ring, 1 disulfide bond, 3 changed amino acids.

Formula

C₄₉H₆₆N₁₀O₁₀S₂

Molecular weight

1,019.2 g/mol

CAS number

83150-76-9

Target

Somatostatin receptors: agonistEvidence: IUPHAR/BPS Guide to PHARMACOLOGY records human SST2, SST3, and SST5 receptor agonism.

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 448601, ChEMBL CHEMBL1680, UNII RWM8CCW8GP, DrugBank DB00104

Full sequence, SMILES and InChIKey

Three-letter sequence
D-Phe-L-Cys-L-Phe-D-Trp-L-Lys-L-Thr-L-Cys-L-threoninol

InChIKey
DEQANNDTNATYII-OULOTJBUSA-N

SMILES
C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O

See charge, composition and 3D structure on the Scientific page

The evidence

What octreotide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people711 of 816 results come from studies in people, including randomized trials.

Growth hormone and growth

145 results · 134 in people · 11 animal

In acromegaly, octreotide LAR achieved biochemical control less often than pasireotide LAR. The Journal of clinical endocrinology and metabolism, 2014

Top results

In acromegaly, octreotide LAR achieved biochemical control less often than pasireotide LAR. (The Journal of clinical endocrinology and metabolism, 2014)
In diabetic rats, octreotide reduced kidney IGF-I versus untreated rats. (Kidney international, 1992)
In acromegaly, IGF-I normalization was numerically lower with octreotide than pegvisomant, without statistical significance. (Journal of endocrinological investigation, 2009)

Stomach and gut

129 results · 128 in people · 1 animal

In variceal bleeding, treatment success was numerically lower with octreotide than terlipressin. Hepatology, 2014

Top results

In variceal bleeding, treatment success was numerically lower with octreotide than terlipressin. (Hepatology, 2014)
In healthy volunteers, octreotide increased average stool fat loss to 19.2 g/day versus placebo. (Digestion, 1987)
In controls, octreotide prolonged mouth to caecum transit compared with saline. (Gut, 1996)

Cancer

83 results · 67 in people · 16 animal

In postmenopausal women with early breast cancer, adding octreotide to tamoxifen did not significantly change event-free survival versus tamoxifen alone. Journal of clinical oncology, 2011

Top results

In postmenopausal women with early breast cancer, adding octreotide to tamoxifen did not significantly change event-free survival versus tamoxifen alone. (Journal of clinical oncology, 2011)
In newly diagnosed acromegaly, substantial tumor shrinkage was less frequent with initial octreotide than initial surgery. (Clinical endocrinology, 2009)
In carcinoid syndrome, stool frequency control was similar across octreotide LAR and SC treatment groups. (Journal of clinical oncology, 1999)

Blood sugar

47 results · 47 in people

In acromegaly, fasting glucose fell less with pegvisomant-octreotide than pegvisomant alone. Clinical endocrinology, 2009

Top results

In acromegaly, fasting glucose fell less with pegvisomant-octreotide than pegvisomant alone. (Clinical endocrinology, 2009)
In patients with cirrhosis, octreotide limited the insulin increase after eating compared with placebo. (Journal of hepatology, 1994)
In children with hypothalamic obesity, octreotide reduced the insulin response to glucose compared with placebo. (The Journal of clinical endocrinology and metabolism, 2003)

Survival and serious illness

45 results · 45 in people

In advanced gastrointestinal cancer refractory to chemotherapy, octreotide increased survival versus supportive care. British journal of cancer, 1995

Top results

In advanced gastrointestinal cancer refractory to chemotherapy, octreotide increased survival versus supportive care. (British journal of cancer, 1995)
In cirrhotic patients with variceal bleeding, deaths were numerically fewer with octreotide than terlipressin, without a significant difference. (The American journal of gastroenterology, 2009)
After pancreatic surgery, hospital deaths occurred in 1% with octreotide versus 0% with saline. (Annals of surgery, 2000)

Heart and blood vessels

52 results · 39 in people · 13 animal

In cirrhotic patients, octreotide changed arterial pressure transiently from baseline. The American journal of gastroenterology, 2005

Top results

In cirrhotic patients, octreotide changed arterial pressure transiently from baseline. (The American journal of gastroenterology, 2005)
In cirrhotic patients, octreotide changed heart rate transiently from baseline. (The American journal of gastroenterology, 2005)
In cirrhotic patients, octreotide reduced portal pressure from baseline at 1 min. (The American journal of gastroenterology, 2005)

Octreotide has 2,449 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 134 octreotide studies by area Open the Scientific page

Key octreotide studies

Studies in people come first, then studies in animals and in the lab.

People
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14
Pritchard et al. 2011 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 667 people · cited by 62
7 results
People
Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage
Seo et al. 2014 · Hepatology (Baltimore, Md.) · 521 people · cited by 141
12 results
People
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study
Colao et al. 2014 · The Journal of clinical endocrinology and metabolism · 358 people · cited by 294
5 results
People
Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial
Yeo et al. 2000 · Annals of surgery · 211 people · cited by 373
4 results
People
Sclerotherapy with or without octreotide for acute variceal bleeding
Besson et al. 1995 · The New England journal of medicine · 199 people · cited by 164
6 results

All 134 Octreotide studies

Octreotide clinical trials

ClinicalTrials.gov lists 256 trials of octreotide. 30 are active or planned, and 56 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding

Phase 4completed1,034 people

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

Phase 3completed429 people

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase 3active, not recruiting427 planned

All 71 Octreotide trials

Status and safety

Is octreotide approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Sandostatin). The FDA label for Sandostatin says: “Reduction of GH and IGF-1 in acromegaly after inadequate response to, or inability to receive, surgery, pituitary irradiation, and maximally tolerated bromocriptine” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Octreotide side effects and safety

PepBank has 118 safety results from studies of octreotide. 116 of them come from studies in people.

Safety results from studies (118)

After pancreatic surgery, fistula rates were 11% with octreotide and 9% with saline. (Annals of surgery, 2000)
In acromegaly, adverse event numbers did not differ between pegvisomant plus octreotide and pegvisomant alone. (Clinical endocrinology, 2009)
In uncontrolled acromegaly, safety results were similar between octreotide regimens except HbA1c. (European journal of endocrinology, 2009)
In newly diagnosed acromegaly, gastrointestinal adverse events were more frequent with initial octreotide than initial surgery. (Clinical endocrinology, 2009)
In variceal bleeding, mortality was numerically higher with octreotide than terlipressin. (Hepatology, 2014)
In cirrhotic patients with variceal bleeding, deaths were numerically fewer with octreotide than terlipressin, without a significant difference. (The American journal of gastroenterology, 2009)
In acute pancreatitis, mortality was 15% with octreotide 100 microg versus 16% with placebo, without a significant difference. (Gut, 1999)
After node surgery, infection counts showed no important difference between octreotide and no treatment. (Journal of the American College of Surgeons, 2003)
After pancreatic surgery, mortality was numerically lower with octreotide than placebo within 90 days. (American journal of surgery, 1992)
In ERCP patients, serum amylase did not differ significantly between octreotide and saline at baseline, eight, and 24 hours. (Gut, 1992)
In cirrhotic patients after sclerotherapy, minor side effects occurred at similar rates with octreotide and placebo. (The New England journal of medicine, 1995)
In acute variceal bleeding, mortality over 48 hours did not differ significantly between octreotide and sclerotherapy. (Gut, 1997)
In metastatic breast cancer, nausea was more frequent with tamoxifen plus octreotide than with tamoxifen alone. (Cancer, 1999)
After pancreas surgery in patients with a soft pancreas and normal-sized duct, morbidity was lower with octreotide than without, but not significantly. (Journal of gastrointestinal surgery, 2015)
In acute variceal bleeding, hospital mortality did not differ significantly between octreotide and sclerotherapy (reported as 27% vs 20%). (Lancet, 1993)
In patients after variceal ligation, in-hospital mortality was numerically lower with added octreotide than ligation alone, without statistical significance. (Lancet, 1995)
In patients with malignant bowel obstruction, octreotide recipients more often needed hyoscine butylbromide than placebo recipients, potentially reflecting increased colicky pain. (Journal of pain and symptom management, 2015)
In variceal bleeding, deaths within 48 hours were 6% with octreotide versus 12% with terlipressin plus nitroglycerin. (Hepatology, 1993)
In metastatic midgut tumors, seven deaths occurred with octreotide versus nine with placebo. (Journal of clinical oncology, 2009)
In ERCP patients, pancreatitis occurred in 35% with octreotide versus 11% with placebo. (The American journal of gastroenterology, 1992)
In radiation-induced diarrhea, no side effects occurred with octreotide or diphenoxylate and atropine. (International journal of radiation oncology, biology, physics, 2002)
In cirrhotic patients, infusion side effects were less frequent with octreotide than vasopressin. (Journal of hepatology, 1992)
In chemotherapy-induced diarrhea, no side effects were observed with octreotide or loperamide. (Journal of clinical oncology, 1993)
In patients with active variceal bleeding, treatment tolerance was better with octreotide than oesophageal tamponade. (Digestion, 1990)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
90 mg monthly	Human	human	intramuscular	2 years	Randomized trial in people · n = 667	Pritchard 2011
20 mg/28 days, with optional titration to 30 mg at months 3 and 7	Human	human	Not reported	12 months	Randomized trial in people · n = 358	Colao 2014
250 microg every 8 hours	Human	human	subcutaneous	7 days	Randomized trial in people · n = 211	Yeo 2000
25 micrograms per hour	Human	human	continuous infusion	five days	Randomized trial in people · n = 199	Besson 1995
200 micrograms three times a day for 5 days a week	Human	human	Not reported	Not reported	Randomized trial in people · n = 107	Cascinu 1995
600 μg/24 hours	Human	human	infusion	Not reported	Randomized trial in people · n = 87	Currow 2015
30 mg monthly	Human	human	intramuscular	Not reported	Randomized trial in people · n = 85	Rinke 2009
100 microg three times daily	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 61	Yavuz 2002
40 mg monthly	Human	human	Not reported	3 years	Randomized trial in people · n = 27	Pisani 2016
60 mg/28 days	Human	human	intramuscular	24 weeks	Randomized trial in people · n = 26	Giustina 2009
2 injections of 20 mg every 28 days	Human	human	intramuscular	Not reported	Randomized trial in people	Perico 2019
40 mg every 28 days	Human	human	Not reported	6 months	Randomized trial in people · n = 12	Caroli 2010
20 mg every 28 days, with adjustment to 30 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 104	Colao 2009
0.3 mg infusion followed by 0.1 mg at 6 and 12 h after infusion	Human	human	intravenous and subcutaneous	Intravenous infusion from 1 h before endoscopy to 6 h after; subcutaneous doses at 6 and 12 h after the infusion stopped	Randomized trial in people · n = 832	Li 2007
100 microg three times daily	Human	human	subcutaneous	seven days	Randomized trial in people · n = 302	Uhl 1999
200 microg three times daily	Human	human	subcutaneous	seven days	Randomized trial in people · n = 302	Uhl 1999
100 or 200 microg three times daily	Human	human	subcutaneous	seven days	Randomized trial in people · n = 302	Uhl 1999
30 mg once every 4 weeks	Human	human	intramuscular	up to 2 years	Randomized trial in people · n = 272	Barbare 2009
0.1 mg three times a day	Human	human	subcutaneous	5 days	Randomized trial in people · n = 261	Carcoforo 2003
0.1 mg every 8 h	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 252	Pederzoli 1994
3 x 100 micrograms	Human	human	subcutaneous	7 days perioperatively	Randomized trial in people · n = 246	Büchler 1992
100 micrograms, given intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP	Human	human	intravenous then subcutaneous	Not reported	Randomized trial in people · n = 245	Binmoeller 1992
0.1 mg at 120 and 30 min before EST and four hours after	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 151	Arcidiacono 1994
50 pg/h	Human	human	intravenous infusion	48 hour	Randomized trial in people · n = 150	Jenkins 1997
150 microg thrice daily	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 135	Ingle 1999
30 mg every 4 weeks	Human	human	intramuscular	Not reported	Randomized trial in people · n = 120	Becker 2007
50 micrograms bolus plus 50 micrograms per h infusion	Human	human	intravenous	48 h	Randomized trial in people · n = 100	Sung 1993
50 micrograms bolus, then 50 micrograms per h	Human	human	intravenous	5 days	Randomized trial in people · n = 94	Sung 1995
25 micrograms/hr	Human	human	intravenous infusion	12 hr	Randomized trial in people · n = 87	Silvain 1993
25 micrograms/hr over 12 hr, then 100 micrograms at hr 12 and hr 18	Human	human	intravenous infusion followed by subcutaneous injection	Not reported	Randomized trial in people · n = 87	Silvain 1993
30 mg monthly	Human	human	Not reported	until tumor progression or death	Randomized trial in people · n = 85	Rinke 2017
100 micrograms before ERCP and 100 micrograms 45 min after initial dose	Human	human	intravenous then subcutaneous	Not reported	Randomized trial in people · n = 84	Sternlieb 1992
600-800 microg/day	Human	human	continuous subcutaneous	Not reported	Randomized trial in people · n = 68	Mystakidou 2002
20 mg every 28th day	Human	human	intramuscular	6 months	Randomized trial in people · n = 61	Carlsen 2008
250 micrograms twice daily	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 58	Kouroumalis 1998
100 micrograms bolus then 25 micrograms/h	Human	human	intravenous infusion	6 h	Randomized trial in people · n = 48	Hwang 1992
0.1 mg twice per day	Human	human	subcutaneous	3 days	Randomized trial in people · n = 41	Cascinu 1993
25 micrograms/h	Human	human	infusion	48 h	Randomized trial in people · n = 40	McKee 1990
100 micrograms every 8 h	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 31	Sancho 1995
470 +/- 160 micrograms daily	Human	human	Not reported	16.5 +/- 10 weeks	Randomized trial in people · n = 24	Kristof 1999

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label reports prescription use. The regimen below is label information.

Reported routines and cautions

What people use it for

Initial short-acting Sandostatin Injection for acromegaly after inadequate response to, or inability to receive, surgery, pituitary irradiation, and maximally tolerated bromocriptine.S1

Reported regimens

Regimens that community sources report for Octreotide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Initial short-acting Sandostatin Injection for acromegaly after inadequate response to, or inability to receive, surgery, pituitary irradiation, and maximally tolerated bromocriptine.Official label dosing of an approved product	subcutaneous injectionThe label specifies systematic rotation of injection sites.	50 mcg per dose	three times daily	initial 2 weeks	Single official US label source.	S1

Cautions

The label warns about glucose disturbances, gallbladder disease, thyroid changes, and cardiac conduction effects.S1

Status notes

EMA lists nationally authorised octreotide products. This is not a current central authorisation for every formulation. The European Commission withdrew Mycapssa on 26 February 2025 at the holder’s request for commercial reasons. This does not withdraw all octreotide products.S2 S3

Community sources

S1Sandostatin US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu
S3EMA Mycapssa withdrawal (opens in a new tab)ema.europa.eu

Gaps

This record covers one selected label regimen. It does not establish a separate community regimen. The full label includes maintenance treatment, other patient groups, monitoring, contraindications, and administration conditions.

Questions and more

Ask a question about octreotide

The answer links to every study it uses.

What does the evidence say about octreotide?Is octreotide tested in people?Compare with Lanreotide Compare with GHRP-6

Sources

Database: PepBank data for octreotide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about octreotide

Octreotide

ApprovedNot banned in sport

Also known as SMS 201-995, SMS-201-995, Sandostatin

What it is

Synthetic analog, 8 amino acids

Approval

Approved in the US and EU (Sandostatin)

In sport

Not listed as banned by WADA

Studies

134 studies with results. All of them gave octreotide, with 816 results.
711 in people105 in animals

Best study in people

Randomized controlled trial with 667 people (2011)

Clinical trials

256 registered: 30 active or planned, 56 with posted results

Community use

Initial short-acting Sandostatin Injection for acromegaly after inadequate response to, or inability to receive, surgery, pituitary irradiation, and maximally tolerated bromocriptine.

Dose as reported

Class

Species

Route

Duration

Design

Source

90 mg monthly

Human

human

intramuscular

2 years

Randomized trial in people · n = 667

Pritchard 2011

20 mg/28 days, with optional titration to 30 mg at months 3 and 7

Human

human

Not reported

12 months

Randomized trial in people · n = 358

Colao 2014

250 microg every 8 hours

Human

human

subcutaneous

7 days

Randomized trial in people · n = 211

Yeo 2000

25 micrograms per hour

Human

human

continuous infusion

five days

Randomized trial in people · n = 199

Besson 1995

200 micrograms three times a day for 5 days a week

Human

human

Not reported

Randomized trial in people · n = 107

Cascinu 1995

600 μg/24 hours

Human

human

infusion

Not reported

Randomized trial in people · n = 87

Currow 2015

30 mg monthly

Human

human

intramuscular

Not reported

Randomized trial in people · n = 85

Rinke 2009

100 microg three times daily

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 61

Yavuz 2002

40 mg monthly

Human

human

Not reported

3 years

Randomized trial in people · n = 27

Pisani 2016

60 mg/28 days

Human

human

intramuscular

24 weeks

Randomized trial in people · n = 26

Giustina 2009

2 injections of 20 mg every 28 days

Human

human

intramuscular

Not reported

Randomized trial in people

Perico 2019

40 mg every 28 days

Human

human

Not reported

6 months

Randomized trial in people · n = 12

Caroli 2010

20 mg every 28 days, with adjustment to 30 mg

Human

human

Not reported

Randomized trial in people · n = 104

Colao 2009

0.3 mg infusion followed by 0.1 mg at 6 and 12 h after infusion

Human

human

intravenous and subcutaneous

Intravenous infusion from 1 h before endoscopy to 6 h after; subcutaneous doses at 6 and 12 h after the infusion stopped

Randomized trial in people · n = 832

Li 2007

100 microg three times daily

Human

human

subcutaneous

seven days

Randomized trial in people · n = 302

Uhl 1999

200 microg three times daily

Human

human

subcutaneous

seven days

Randomized trial in people · n = 302

Uhl 1999

100 or 200 microg three times daily

Human

human

subcutaneous

seven days

Randomized trial in people · n = 302

Uhl 1999

30 mg once every 4 weeks

Human

human

intramuscular

up to 2 years

Randomized trial in people · n = 272

Barbare 2009

0.1 mg three times a day

Human

human

subcutaneous

5 days

Randomized trial in people · n = 261

Carcoforo 2003

0.1 mg every 8 h

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 252

Pederzoli 1994

3 x 100 micrograms

Human

human

subcutaneous

7 days perioperatively

Randomized trial in people · n = 246

Büchler 1992

100 micrograms, given intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP

Human

human

intravenous then subcutaneous

Not reported

Randomized trial in people · n = 245

Binmoeller 1992

0.1 mg at 120 and 30 min before EST and four hours after

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 151

Arcidiacono 1994

50 pg/h

Human

human

intravenous infusion

48 hour

Randomized trial in people · n = 150

Jenkins 1997

150 microg thrice daily

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 135

Ingle 1999

30 mg every 4 weeks

Human

human

intramuscular

Not reported

Randomized trial in people · n = 120

Becker 2007

50 micrograms bolus plus 50 micrograms per h infusion

Human

human

intravenous

48 h

Randomized trial in people · n = 100

Sung 1993

50 micrograms bolus, then 50 micrograms per h

Human

human

intravenous

5 days

Randomized trial in people · n = 94

Sung 1995

25 micrograms/hr

Human

human

intravenous infusion

12 hr

Randomized trial in people · n = 87

Silvain 1993

25 micrograms/hr over 12 hr, then 100 micrograms at hr 12 and hr 18

Human

human

intravenous infusion followed by subcutaneous injection

Not reported

Randomized trial in people · n = 87

Silvain 1993

30 mg monthly

Human

human

Not reported

until tumor progression or death

Randomized trial in people · n = 85

Rinke 2017

100 micrograms before ERCP and 100 micrograms 45 min after initial dose

Human

human

intravenous then subcutaneous

Not reported

Randomized trial in people · n = 84

Sternlieb 1992

600-800 microg/day

Human

human

continuous subcutaneous

Not reported

Randomized trial in people · n = 68

Mystakidou 2002

20 mg every 28th day

Human

human

intramuscular

6 months

Randomized trial in people · n = 61

Carlsen 2008

250 micrograms twice daily

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 58

Kouroumalis 1998

100 micrograms bolus then 25 micrograms/h

Human

human

intravenous infusion

6 h

Randomized trial in people · n = 48

Hwang 1992

0.1 mg twice per day

Human

human

subcutaneous

3 days

Randomized trial in people · n = 41

Cascinu 1993

25 micrograms/h

Human

human

infusion

48 h

Randomized trial in people · n = 40

McKee 1990

100 micrograms every 8 h

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 31

Sancho 1995

470 +/- 160 micrograms daily

Human

human

Not reported

16.5 +/- 10 weeks

Randomized trial in people · n = 24

Kristof 1999

Context

Route

Amount

How often

How long

Agreement

Sources

Initial short-acting Sandostatin Injection for acromegaly after inadequate response to, or inability to receive, surgery, pituitary irradiation, and maximally tolerated bromocriptine.Official label dosing of an approved product

subcutaneous injectionThe label specifies systematic rotation of injection sites.

50 mcg per dose

three times daily

initial 2 weeks

Single official US label source.

Octreotide

Octreotide at a glance

What is octreotide?

The history of octreotide

Octreotide structure and chemistry

What octreotide studies show

Growth hormone and growth

Stomach and gut

Cancer

Blood sugar

Survival and serious illness

Heart and blood vessels

Key octreotide studies

Octreotide clinical trials

Is octreotide approved?

Octreotide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about octreotide

Related peptides

Sources

Octreotide

Octreotide at a glance

What is octreotide?

The history of octreotide

Octreotide structure and chemistry

What octreotide studies show

Growth hormone and growth

Stomach and gut

Cancer

Blood sugar

Survival and serious illness

Heart and blood vessels

Key octreotide studies

Octreotide clinical trials

Is octreotide approved?

Octreotide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about octreotide

Related peptides

Sources